Back to top
more

Evotec (EVO)

(Delayed Data from NSDQ)

$3.75 USD

3.75
7,292

+0.04 (1.08%)

Updated Aug 30, 2024 11:39 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for EVO

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Evotec AG falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 654 757 1,015 551 358
Receivables 194 238 187 125 119
Notes Receivable 0 0 0 0 0
Inventories 33 31 31 16 12
Other Current Assets 96 104 70 61 36
Total Current Assets 977 1,131 1,303 753 526
Net Property & Equipment 873 685 573 385 268
Investments & Advances 154 155 333 67 46
Other Non-Current Assets 102 74 66 42 25
Deferred Charges 16 11 21 29 38
Intangibles 315 315 341 395 418
Deposits & Other Assets 1 7 7 1 1
Total Assets 2,438 2,378 2,644 1,671 1,323
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 145 102 86 49 35
Current Portion Long-Term Debt 0 2 43 18 7
Current Portion Capital Leases 0 16 17 17 16
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 6 9 13 4 8
Other Current Liabilities 351 227 226 151 134
Total Current Liabilities 503 356 384 238 200
Mortgages 0 0 0 0 0
Deferred Taxes/Income 20 20 22 28 29
Convertible Debt 0 0 0 0 0
Long-Term Debt 516 346 386 378 364
Non-Current Capital Leases 0 171 161 150 132
Other Non-Current Liabilities 187 236 61 52 63
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 1,226 1,127 1,014 845 788
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 192 186 209 187 169
Capital Surplus 1,569 1,517 1,692 1,177 881
Retained Earnings -515 -413 -256 -496 -494
Other Equity -33 -39 -15 -43 -22
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 1,212 1,251 1,630 826 534
Total Liabilities & Shareholder's Equity 2,438 2,378 2,644 1,671 1,323
Total Common Equity 1,212 1,251 1,630 826 534
Shares Outstanding 354.30 353.90 350.80 327.80 301.80
Book Value Per Share 3.42 3.53 4.65 2.52 1.77

Fiscal Year End for Evotec AG falls in the month of December.

All items in Millions except Per Share data.

6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Assets          
Cash & Equivalents 322 554 654 668 677
Receivables 242 199 194 209 289
Notes Receivable 0 0 0 0 0
Inventories 40 35 33 35 36
Other Current Assets 102 110 96 111 118
Total Current Assets 706 897 977 1,022 1,119
Net Property & Equipment 883 898 873 831 786
Investments & Advances 139 147 154 165 175
Other Non-Current Assets 74 111 102 107 97
Deferred Charges 32 24 16 11 12
Intangibles 319 320 315 317 319
Deposits & Other Assets 0 1 1 0 0
Total Assets 2,153 2,398 2,438 2,454 2,509
Liabilities & Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Notes Payable 0 0 0 0 0
Accounts Payable 94 108 145 105 116
Current Portion Long-Term Debt 0 168 0 0 165
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 9 6 6 8 11
Other Current Liabilities 282 199 351 359 240
Total Current Liabilities 385 481 503 472 532
Mortgages 0 0 0 0 0
Deferred Taxes/Income 16 20 20 20 21
Convertible Debt 0 0 0 0 0
Long-Term Debt 461 513 516 1 417
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 201 187 719 259
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 1,063 1,197 1,226 1,212 1,229
Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Preferred Stock 0 0 0 0 0
Common Stock (Par) 191 193 192 193 193
Capital Surplus 1,562 1,573 1,569 1,574 1,576
Retained Earnings -637 -540 -515 -526 -489
Other Equity -27 -25 -33 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 1,089 1,201 1,212 1,242 1,280
Total Liabilities & Shareholder's Equity 2,153 2,398 2,438 2,454 2,509
Total Common Equity 1,089 1,201 1,212 1,242 1,280
Shares Outstanding 354.30 354.30 354.30 354.30 353.90
Book Value Per Share 3.07 3.39 3.42 3.50 3.62